Advances in the hypoxia-responsive antitumor drug nanocarriers and tumor hypoxia relieve

LIANG Jinlai; XU Wei; YIN Tingjie; HUO Meirong

doi:10.11665/j.issn.1000-5048.20180301

Journal of China Pharmaceutical University > 2018 > 49(3): 255-262. > DOI: 10.11665/j.issn.1000-5048.20180301

LIANG Jinlai, XU Wei, YIN Tingjie, HUO Meirong. Advances in the hypoxia-responsive antitumor drug nanocarriers and tumor hypoxia relieve[J]. Journal of China Pharmaceutical University, 2018, 49(3): 255-262. DOI: 10.11665/j.issn.1000-5048.20180301

Citation:

PDF (1404 KB)

Advances in the hypoxia-responsive antitumor drug nanocarriers and tumor hypoxia relieve

More Information

Graphical Abstract

Abstract

Abstract

Hypoxia, a salient feature of solid tumors, is often associated with invasiveness, metastasis and resistance to anticancer drugs. The strategies including the use of oxygen-carriers based on hyperbaric oxygen and blood substitutes to transport oxygen into tumors or in situ generation of O₂ from the tumor microenvironment endogenous H₂O₂ have been explored to relieve the tumor hypoxia and to improve therapeutic efficiency. In addition, it is potential to design hypoxia-responsive nanocarriers based on tumor hypoxia microenvironment to deliver anticancer drugs to the targeted tumor site, thereby improve drug concentrations in targeted site, significantly increase the antitumor efficiency and reduce the side-effects of drugs. This review gives an overview of the advances in relieving tumor hypoxia and hypoxia-responsive nanocarriers for tumor to provide a reference for the research and development of new antitumor drugs.
- hypoxia,
- oxygen delivery,
- H₂O₂,
- hypoxia environment,
- hypoxia-responsive,
- nanocarriers,
- antitumor

FullText(HTML)

References (47)

References

[1]	Alimoradi H,Matikonda SS,Gamble AB,et al.Hypoxia responsive drug delivery systems in tumor therapy[J].Curr Pharm Des,2016,22(19):2808-2820.
[2]	Rapisarda A,Melillo G.Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies[J].Drug Resist Updat,2009,12(3):74-80.
[3]	Bryant JL,Meredith SL,Williams KJ,et al.Targeting hypoxia in the treatment of small cell lung cancer[J].Lung Cancer,2014,86(2):126-32.
[4]	Du J,Lane LA,Nie S.Stimuli-responsive nanoparticles for targeting the tumor microenvironment[J].J Control Release,2015,219:205-214.
[5]	Khawar IA,Kim JH,Kuh HJ.Improving drug delivery to solid tumors:priming the tumor microenvironment[J].J Control Release,2015,201:78-89.
[6]	Moen I, Stuhr LE. Hyperbaric oxygen therapy and cancer—a review[J].Target Oncol,2012,7(4):233-242.
[7]	Alam F,Yadav N,Ahmad M,et al.Blood substitutes:possibilities with nanotechnology[J].Indian J Hematol Blood Transfus,2014,30(3):155-162.
[8]	Spahn DR.Blood substitutes.Artificial oxygen carriers:perfluorocarbon emulsions[J].Crit Care,1999,3(5):R93-97.
[9]	Greenburg AG,Kim HW.Hemoglobin-based oxygen carriers[J].Crit Care,2004,8(Suppl 2):S61-S64.
[10]	Yuan J,Cen Y,Kong XJ,et al.MnO₂-nanosheet-modified upconversion nanosystem for sensitive turn-on fluorescence detection of H₂O₂ and glucose in blood[J].ACS Appl Mater Interfaces,2015,7(19):10548-10555.
[11]	Fan W, Bu W, Shen B, et al. Intelligent MnO₂ nanosheets anchored with upconversionnanoprobes for concurrent pH-/H₂O₂-responsive UCL imaging and oxygen-elevated synergetic therapy[J].Adv Mater,2015,27(28):4155-4161.
[12]	Stępień K, Ostrowski RP, Matyja E. Hyperbaric oxygen as an adjunctive therapy in treatment of malignancies,including brain tumours[J].Med Oncol,2016,33(9):101.
[13]	Peng HS,Liao MB,Zhang MY,et al.Synergistic inhibitory effect of hyperbaric oxygen combined with sorafenib on hepatoma cells[J].PLoS One,2014,9(6):e100814.
[14]	Lu Z, Ma J, Liu B, et al. Hyperbaric oxygen therapy sensitizes nimustine treatment for glioma in mice[J].Cancer Med,2016,5(11):3147-3155.
[15]	Hartmann KA,van der Kleij AJ,Carl UM,et al.Effects of hyperbaric oxygen and normobaric carbogen on the radiation response of the rat rhabdomyosarcoma R1H[J].Int J Radiat Oncol Biol Phys,2001,51(4):1037-1044.
[16]	Wu W,Yang Q,Li T,et al.Hemoglobin-based oxygen carriers combined with anticancer drugs may enhance sensitivity of radiotherapy and chemotherapy to solid tumors[J].Artif Cells Blood Substit Immobil Biotechnol,2009,37(4):163-165.
[17]	Vásquez DM,Ortiz D,Alvarez OA,et al.Hemorheological implications of perfluorocarbon based oxygen carrier interaction with colloid plasma expanders and blood[J].Biotechnol Prog,2013,29(3):796-807.
[18]	Riess JG.Perfluorocarbon-based oxygen delivery[J].Artif Cells Blood Substit Immobil Biotechnol,2006,34(6):567-580.
[19]	Li F,Mei H,Gao Y,et al.Co-delivery of oxygen and erlotinib by aptamer-modified liposomal complexes to reverse hypoxia-induced drug resistance in lung cancer[J].Biomaterials,2017,145:56-71.
[20]	Luo Z,Zheng M,Zhao P,et al.Self-monitoring artificial red cells with sufficient oxygen supply for enhanced photodynamic therapy[J].Sci Rep,2016,6:23393.
[21]	Cheng Y,Cheng H,Jiang C,et al.Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy[J].Nat Commun,2015,6:8785.
[22]	Song X,Feng L,Liang C,et al.Ultrasound triggered tumor oxygenation with oxygen-shuttle nanoperfluorocarbon to overcome hypoxia-associated resistance in cancer therapies[J].Nano Lett,2016,16(10):6145-6153.
[23]	Zhang L,Li J,Zong L,et al.Reactive oxygen species and targeted therapy for pancreatic cancer[J].Oxid Med Cell Longev,2016,2016(3):1616781.
[24]	Vilema-Enríquez G,Arroyo A,Grijalva M,et al.Molecular and cellular effects of hydrogen peroxide on human lung cancer cells:potential therapeutic implications[J].Oxid Med Cell Longev,2016,2016(6):1-12.
[25]	Lennicke C,Rahn J,Lichtenfels R,et al.Hydrogen peroxide-production,fate and role in redox signaling of tumor cells[J].Cell Commun Signal,2015,13:39.
[26]	Chen Q, Chen J, Liang C, et al. Drug-induced co-assembly of albumin/catalase as smart nano-theranostics for deep intra-tumoral penetration,hypoxia relieve,and synergistic combination therapy[J].J Control Release,2017,263:79-89.
[27]	Prasad P,Gordijo CR,Abbasi AZ,et al.Multifunctional albumin-MnO₂ nanoparticles modulate solid tumor microenvironment by attenuating hypoxia,acidosis,vascular endothelial growth factor and enhance radiation response[J].ACS Nano,2014,8(4):3202-3212.
[28]	Chen H,He W,Guo Z.An H₂O₂-responsive nanocarrier for dual-release of platinum anticancer drugs and O₂:controlled release and enhanced cytotoxicity against cisplatin resistant cancer cells[J].Chem Commun(Camb),2014,50(68):9714-9717.
[29]	Chen H,Tian J,He W,et al.H₂O₂-activatable and O₂-evolving nanoparticles for highly efficient and selective photodynamic therapy against hypoxic tumor cells[J].J Am Chem Soc,2015,137(4):1539-1547.
[30]	Song G,Chen Y,Liang C,et al.Catalase-loaded TaOx nanoshells as bio-nanoreactors combining high-Z element and enzyme delivery for enhancing radiotherapy[J].Adv Mater,2016,28(33):7143-7148.
[31]	Zhu W,Dong Z,Fu T,et al.Modulation of hypoxia in solid tumor microenvironment with MnO₂ nanoparticles to enhance photodynamic therapy[J].Adv Funct Mater,2016,26(30):5490-5498.
[32]	Gao S,Wang G,Qin Z,et al.Oxygen-generating hybrid nanoparticles to enhance fluorescent/photoacoustic/ultrasound imaging guided tumor photodynamic therapy[J].Biomaterials,2017,112:324-335.
[33]	Phillips RM. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs[J].Cancer Chemother Pharmacol,2016,77(3):441-457.
[34]	Guise CP,Mowday AM,Ashoorzadeh A,et al.Bioreductive prodrugs as cancer therapeutics:targeting tumor hypoxia[J].Chin J Cancer,2014,33(2):80-86.
[35]	Denny WA.Hypoxia-activated prodrugs in cancer therapy:progress to the clinic[J].Future Oncol,2010,6(3):419-428.
[36]	Denny WA,Wilson WR,Hay MP.Recent developments in the design of bioreductive drugs[J].Br J Cancer Suppl,1996,27:S32-S38.
[37]	Mistry IN, Thomas M, Calder EDD, et al. Clinical advances of hypoxia-activated prodrugs in combination with radiation therapy[J].Int J Radiat OncolBiol Phys,2017,98(5):1183-1196.
[38]	Feng L, Cheng L, Dong Z, et al. Theranostic liposomes with hypoxia-activated prodrug to effectively destruct hypoxic tumors post-photodynamic therapy[J].ACS Nano,2017,11(1):927-937.
[39]	Li SY, Cheng H, Qiu WX, et al. Cancer cell membrane-coated biomimetic platform for tumor targeted photodynamic therapy and hypoxia-amplified bioreductive therapy[J].Biomaterials,2017,142:149-161.
[40]	Wang Y,Xie Y,Li J,et al.Tumor-penetrating nanoparticles for enhanced anticancer activity of combined photodynamic and hypoxia-activated therapy[J].ACS Nano,2017,11(2):2227-2238.
[41]	Thambi T,Park JH,Lee DS.Hypoxia-responsive nanocarriers for cancer imaging and therapy:recent approaches and future perspectives[J].Chem Commun(Camb),2016,52(55):8492-8500.
[42]	Thambi T,Deepagan VG,Yoon HY,et al.Hypoxia-responsive polymeric nanoparticles for tumor-targeted drug delivery[J].Biomaterials,2014,35(5):1735-1743.
[43]	Kang L,Fan B,Sun P,et al.An effective tumor-targeting strategy utilizing hypoxia-sensitive siRNA delivery system for improved anti-tumor outcome[J].Acta Biomater,2016,44:341-354.
[44]	Ahmad Z,Lv S,Tang Z,et al.Methoxy poly(ethylene glycol)-block-poly(glutamic acid)-graft-6-(2-nitroimidazole)hexyl amine nanoparticles for potential hypoxia-responsive delivery of doxorubicin[J].J Biomater Sci Polym Ed,2016,27(1):40-54.
[45]	Liu H,Zhang R,Niu Y,et al.Development of hypoxia-triggered prodrug micelles as doxorubicin carriers for tumor therapy[J].RSC Adv,2015,5(27):20848-20857.
[46]	Perche F,Biswas S,Wang T,et al.Hypoxia-targeted siRNA delivery[J].Angew Chem Int Ed Engl,2014,53(13):3362-3366.
[47]	Kulkarni P,Haldar MK,You S,et al.Hypoxia-responsive polymersomes for drug delivery to hypoxic pancreatic cancer cells[J].Biomacromolecules,2016,17(8):2507-2513.

Cited By

Get Citation

PDF

XML

Article views (1473) PDF downloads (4467)

Turn off MathJax

Article Contents

Abstract

References

Advances in the hypoxia-responsive antitumor drug nanocarriers and tumor hypoxia relieve

Abstract

References

Catalog

Export File

Citation

Format

Content